{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:06:36Z","timestamp":1717805196540},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.3892\/mmr.2015.3519","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T09:46:44Z","timestamp":1426844804000},"page":"1449-1456","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms"],"prefix":"10.3892","volume":"12","author":[{"given":"XIAONING","family":"WANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEI","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"key20180108023018_b1-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/OTT.S67165","article-title":"Arsenic trioxide-based therapy in relapsed\/refractory multiple myeloma patients: A meta-analysis and systematic review","volume":"7","author":"He","year":"2014","journal-title":"Onco Targets Ther"},{"key":"key20180108023018_b2-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1056\/NEJMc1104560","article-title":"Multiple myeloma","volume":"364","author":"Spitzer","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108023018_b3-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br J Haematol"},{"key":"key20180108023018_b4-mmr-12-01-1449","first-page":"504","article-title":"Arsenic trioxide in patients with refractory multiple myeloma: A prospective, phase II, single-arm study","volume":"49","author":"Sanaat","year":"2011","journal-title":"Acta Med Iran"},{"key":"key20180108023018_b5-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/sj.leu.2403424","article-title":"A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients","volume":"9","author":"Rousselot","year":"2004","journal-title":"Leukemia"},{"key":"key20180108023018_b6-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"367b","DOI":"10.1182\/blood.V106.11.5135.5135","article-title":"Treatment with asenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: Preliminary findings of a multicenter, phase II study","volume":"106","author":"Wu","year":"2005","journal-title":"Blood"},{"key":"key20180108023018_b7-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2006.06280.x","article-title":"Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: A prospective, multicentre, phase II, single-arm study","volume":"135","author":"Berenson","year":"2006","journal-title":"Br J Haematol"},{"key":"key20180108023018_b8-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.V106.11.2565.2565","article-title":"A phase I\/II trial evaluation the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma","volume":"106","author":"Bertenson","year":"2005","journal-title":"Blood"},{"key":"key20180108023018_b9-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-394387-3.00005-7","article-title":"Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity","volume":"116","author":"Matthews","year":"2012","journal-title":"Adv Cancer Res"},{"key":"key20180108023018_b10-mmr-12-01-1449","first-page":"1288","article-title":"Synergistic effects of VPA and As2O3 on Molt-4 cells in vitro and its possible mechanisms","volume":"16","author":"Ye","year":"2008","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"key20180108023018_b11-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20180108023018_b12-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171\u2013006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"key20180108023018_b13-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy","volume":"13","author":"Kaufman","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20180108023018_b14-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180108023018_b15-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann Hematol"},{"key":"key20180108023018_b16-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"key20180108023018_b17-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"key20180108023018_b18-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur J Haematol"},{"key":"key20180108023018_b19-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.leukres.2013.03.006","article-title":"Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma","volume":"37","author":"Richardson","year":"2013","journal-title":"Leuk Res"},{"key":"key20180108023018_b20-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","article-title":"In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor","volume":"143","author":"Neri","year":"2008","journal-title":"Br J Haematol"},{"key":"key20180108023018_b21-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1586\/14737140.2013.833681","article-title":"Treatment of acute promyelocytic leukemia with arsenic trioxide: Clinical results and open questions","volume":"13","author":"Lengfelder","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180108023018_b22-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLM.2006.n.058","article-title":"Arsenic compounds in the treatment of multiple Myeloma: A new role for a historical remedy","volume":"7","author":"Berenson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"key20180108023018_b23-mmr-12-01-1449","first-page":"504","article-title":"Arsenic trioxide in patients with refractory multiple myeloma: A prospective, phase II, single-arm study","volume":"49","author":"Sanaat","year":"2011","journal-title":"Acta Med Iran"},{"key":"key20180108023018_b24-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/07357907.2012.756109","article-title":"A Phase I study of arsenic trioxide (Trisenox), ascorbic acid and bortezomib (Velcade) combination therapy in patients with relapsed\/refractory multiple myeloma","volume":"31","author":"Held","year":"2013","journal-title":"Cancer Invest"},{"key":"key20180108023018_b25-mmr-12-01-1449","first-page":"504","article-title":"Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study","volume":"49","author":"Sanaat","year":"2011","journal-title":"Acta Med Iran"},{"key":"key20180108023018_b26-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cncr.26517","article-title":"A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide and ascorbic acid","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"key20180108023018_b27-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/1871520611009060504","article-title":"Combination therapy with arsenic trioxide for hematological malignancies","volume":"10","author":"Takahashi","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180108023018_b28-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ctrv.2009.04.007","article-title":"The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review","volume":"35","author":"R\u00f6llig","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"key20180108023018_b29-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/10428190903486212","article-title":"Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines","volume":"51","author":"Peng","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"key20180108023018_b30-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"e32215","DOI":"10.1371\/journal.pone.0032215","article-title":"Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6","volume":"7","author":"Qu","year":"2012","journal-title":"PLoSOne"},{"key":"key20180108023018_b31-mmr-12-01-1449","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/cell.2013.0018","article-title":"Effect of histone Deacetylase inhibitor Valproic acid treatment on donor cell growth characteristics, cell cycle arrest, apoptosis and handmade cloned Bovine Embryo production efficiency","volume":"15","author":"Selokar","year":"2013","journal-title":"Cell Reprogram"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2015.3519\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:09:25Z","timestamp":1717801765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2015.3519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,3,20]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3892\/mmr.2015.3519"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2015.3519","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}